<DOC>
	<DOCNO>NCT00003696</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective extensive-stage small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect cyclophosphamide , doxorubicin , etoposide carboplatin paclitaxel progression free survival patient extensive stage small cell lung cancer . - Compare overall survival , response rate , duration response , toxic effect regimens patient . OUTLINE : This randomize study . Patients stratify accord institute performance status ( 0-1 v 2-3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cyclophosphamide IV doxorubicin IV day 1 , etoposide IV day 1-3 every 3 week . - Arm II : Patients receive carboplatin IV follow paclitaxel IV 3 hour day 1 every 3 week . Patients stable respond disease treat 5 course . Patients follow every 4 week . PROJECTED ACCRUAL : A total 250 patient ( 125 per treatment arm ) accrue within 24 month study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven extensive stage small cell lung cancer , previously treat chemotherapy radiotherapy except symptomatic brain metastasis Measurable evaluable disease Ascites , pleural effusion , osteolytic osteoblastic bone metastases measurable evaluable PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 Absolute neutrophil count least 2,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( unless due liver metastasis ) Renal : Creatinine clearance least 60 mL/min Cardiovascular : No cardiac failure rhythm disturbance require medication Other : No history hypersensitivity castor oil No active uncontrolled infection No nonmalignant disease present poor medical risk Not pregnant Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : See Disease Characteristics Palliative radiotherapy allow ( indicator lesion outside irradiated field ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>